Galera presents additional chronic kidney disease data from roman trial at 2023 asco annual meeting

As previously reported, avasopasem reduced cisplatin-related chronic kidney disease by 50% compared to placebo at one-year follow-up
GRTX Ratings Summary
GRTX Quant Ranking